Avalo Therapeutics CMO Sells $20,000 in Company Stock

Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, sold 1,000 shares of company stock on August 17, 2026, for a total of $20,000, according to a recent SEC Form 4 filing. The transaction was executed under a Rule 10b5-1 trading plan adopted on November 13, 2025. Doyle simultaneously acquired 1,000 shares by exercising stock options at an exercise price of $12.65 per share, totaling $12,650. Following these transactions, Doyle directly owns 51,776 shares and holds 123,750 derivative securities in the form of stock options. The stock has returned 83% over the past year, though InvestingPro analysis suggests it may be overvalued at $19.34, near its 52-week high of $24.27. Avalo recently joined the Russell 2000 and 3000 indices and appointed Ron Philip to its board.